Skip to main content
Clinical Trials/NCT06180460
NCT06180460
Completed
Not Applicable

Managing Distress in Malignant Brain Cancer - Phase IIc RCT

Virginia Commonwealth University1 site in 1 country60 target enrollmentNovember 10, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Brain Tumor
Sponsor
Virginia Commonwealth University
Enrollment
60
Locations
1
Primary Endpoint
Assess the feasibility of the CALM intervention- Post-Intervention Questionnaire Completion Rate
Status
Completed
Last Updated
6 months ago

Overview

Brief Summary

The purpose of this study is to test an empirically supported psychotherapeutic intervention, Managing Cancer and Living Meaningfully (CALM), compared to treatment as usual (TAU) in those with malignant brain cancer diagnoses.

Registry
clinicaltrials.gov
Start Date
November 10, 2023
End Date
September 30, 2025
Last Updated
6 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Self-reported diagnosis of brain metastasis (bMET) or a malignant primary brain tumor (PBT; specifically grade III or IV and CNS diffuse large B cell lymphomas)\*
  • At least 2-weeks post-surgical resection or biopsy of the brain (if applicable)
  • Score \> 20 on the TICS
  • Reported elevated depression (PHQ-9 score ≥ 10) OR death anxiety symptoms (DADDS score ≥ 15)
  • Ability to read, speak, and understand English
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

  • Major communication difficulties which would prohibit the psychotherapeutic interaction
  • Inability to meet with the interventionist via an electronic device for telehealth intervention sessions
  • Inability to understand and provide informed consent
  • Prisoners
  • Medical, psychological, or social condition that, in the opinion of the principal investigator, may increase the participant's risk of adverse events and/or prohibit the individual's participation in the intervention.

Outcomes

Primary Outcomes

Assess the feasibility of the CALM intervention- Post-Intervention Questionnaire Completion Rate

Time Frame: 3 months

Percent of consented individuals who complete post-intervention questionnaires

Assess the feasibility of the CALM intervention- Consent Rate

Time Frame: Day 0

Percent of eligible individuals who consent to the trial

Assess the feasibility of the CALM intervention- Screening Rate

Time Frame: Day 0

Percent of interested individuals who undergo screening

Assess the feasibility of the CALM intervention- Follow-up Questionnaire Completion Rate

Time Frame: 6 months

Percent of consented individuals who complete follow-up questionnaires

Assess the feasibility of the CALM intervention- Intervention Retention Rate

Time Frame: 3 months

Percent of consented individuals who complete the CALM intervention

Assess the acceptability of the CALM intervention- Participant Satisfaction

Time Frame: 4 months

Satisfaction ratings from participants during exit interview (e.g., Rate your overall benefit on a scale of 1-5).

Assess the acceptability of the CALM intervention- Participant Recommendation Ratings

Time Frame: 4 months

Percent of participants who would recommendation CALM to others will be assessed during the exit interview (e.g., Would you recommend this program to others?)

Study Sites (1)

Loading locations...

Similar Trials